Labordiagnostik von Fettstoffwechselstörungen

 

 Permissions and Reprints

Abstract

Clinically, disorders of lipid metabolism often remain without symptoms. Typical skin lesions, however, can be indicative. Secondary hyperlipoproteinemias (HLP) are more common than primary hyperlipoproteinemias; they can (partially) be improved by treating the underlying disease. Basic diagnostics consist of the determination of cholesterol, triglycerides, LDL cholesterol and HDL cholesterol. To exclude secondary HLP, glucose, HbA_1C, TSH, transaminases, creatinine, urea, protein and protein in the urine are useful. Since virtually all routine methods for LDL-C are biased by high triglycerides, lipoprotein electrophoresis is indicated for triglycerides above 400 mg/dl (4.7 mmol/l). Primary HLPs have known or yet unknown genetic causes. Primary hyperlipidemias should be taken into consideration especially in young patients with an LDL cholesterol concentration are above 190 mg/dl (4.9 mmol/l) and/or triglycerides above 400 mg/dl (10 mmol/l) and secondary HLP (obesity, alcohol, diabetes mellitus, kidney disease) is excluded. The basic diagnostics is meaningfully extended by the measurement of lipoprotein (a) (Lp(a)). It is indicated in moderate and high risk of vascular disease, progression of atherosclerosis in "well-controlled" LDL cholesterol, familial clustering of atherosclerosis or high Lp(a), evidence for elevated Lp(a) coming from lipoprotein electrophoresis, aortic stenosis and in patients in whom statins have a poor effect. Genetic diagnostics needs to be considered if primary HLP is suspected. It is most frequently conducted for suspected familial hypercholesterolemia and has already been recommended in guidelines.

Publication History

Article published online:
10 November 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188 DOI: 10.1093/eurheartj/ehz455.
  CrossrefPubMedGoogle Scholar
• 2 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337 DOI: 10.1093/eurheartj/ehab484.
  CrossrefPubMedGoogle Scholar
• 3 Blanke P. The distribution of lipoprotein concentrations in Germany. in preparation 2023.
  PubMedGoogle Scholar
• 4 März W, Beil FU, Dieplinger H. Genetic diseases of lipid metabolism – Focus familial hypercholesterolemia. Dtsch Med Wochenschr 2022; 147: e50-e61 DOI: 10.1055/a-1516-2541.
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 März W, Grammer TB, Delgado G. et al. Congenital disorders of lipoprotein metabolism. Herz 2017; 42: 449-458 DOI: 10.1007/s00059-017-4578-x.
  CrossrefPubMedGoogle Scholar
• 6 Katzmann JL, Lehmann M, Tunnemann-Tarr A. et al. Cutaneous manifestations in familial hypercholesterolaemia. Atherosclerosis 2021; 333: 116-123 DOI: 10.1016/j.atherosclerosis.2021.07.007.
  CrossrefPubMedGoogle Scholar
• 7 Langlois MR, Chapman MJ, Cobbaert C. et al. Quantifying atherogenic lipoproteins: Current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem 2018; 64: 1006-1033 DOI: 10.1373/clinchem.2018.287037.
  CrossrefPubMedGoogle Scholar
• 8 Kassenärztliche Bundesvereinigung. Gesundheitsvorsorge: Der Check-up für Erwachsene. Im Internet (Stand: 04.09.2023): www.kbv.de/html/3500.php
  PubMedGoogle Scholar
• 9 Fath F, Bengeser A, Barresi M. et al. FH ALERT: Efficacy of a novel approach to identify patients with familial hypercholesterolemia. Sci Rep 2021; 11: 20421 DOI: 10.1038/s41598-021-99961-y.
  CrossrefPubMedGoogle Scholar
• 10 Gemeinsamer Bundesausschuss. Kinderuntersuchungsheft. Im Internet (Stand: 04.09.2023): www.g-ba.de/downloads/17-98-4160/2023-05-12_G-BA_Kinderuntersuchungsheft_WEB_WZ_PW.pdf
  PubMedGoogle Scholar
• 11 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics 2011; 128 (Suppl. 05) S213-S256 DOI: 10.1542/peds.2009-2107C.
  CrossrefPubMedGoogle Scholar
• 12 Daniels SR, Gidding SS, de Ferranti SD. et al. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5: S30-S37 DOI: 10.1016/j.jacl.2011.03.453.
  CrossrefPubMedGoogle Scholar
• 13 Luirink IK, Wiegman A, Kusters DM. et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381: 1547-1556 DOI: 10.1056/NEJMoa1816454.
  CrossrefPubMedGoogle Scholar
• 14 Ference BA, Ginsberg HN, Graham I. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472 DOI: 10.1093/eurheartj/ehx144.
  CrossrefPubMedGoogle Scholar
• 15 Klose G, Laufs U, März W. et al. Familial hypercholesterolemia: Developments in diagnosis and treatment. Deutsches Ärzteblatt international 2014; 111: 523-529 DOI: 10.3238/arztebl.2014.0523.
  CrossrefPubMedGoogle Scholar
• 16 U.S. Department of Health and Human Services. Public Health Service. National Institutes of Health. Manual of laboratory operations: lipid and lipoprotein analysis (revised). US Government Printing Office, Washington, DC Report No: (NIH) 75-67815. 1982
  PubMedGoogle Scholar
• 17 Nauck M, Winkler K, März W. et al. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995; 41: 1761-1767
  CrossrefPubMedGoogle Scholar
• 18 Nauck M, Winkler K, Wittmann C. et al. Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin Chem 1995; 41: 731-738
  CrossrefPubMedGoogle Scholar
• 19 Rief M, Raggam R, Rief P. et al. Comparison of two nuclear magnetic resonance spectroscopy methods for the measurement of lipoprotein particle concentrations. Biomedicines 2022; 10 DOI: 10.3390/biomedicines10071766.
  CrossrefPubMedGoogle Scholar
• 20 Siekmeier R, März W, Groß W. Precipitation of low density lipoproteins with sulfated polyanions: Three methdod compared. Clin Chem 1988; 177: 221-230
  CrossrefPubMedGoogle Scholar
• 21 Siekmeier R, März W, Groß W. Insufficient accuracy and specificity of polyanion precipitation methods for the quantitation of low density lipoproteteins. Clin Chem 1990; 36: 2109-2113
  CrossrefPubMedGoogle Scholar
• 22 Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002; 48: 236-254
  CrossrefPubMedGoogle Scholar
• 23 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
  CrossrefPubMedGoogle Scholar
• 24 Martin SS, Blaha MJ, Elshazly MB. et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013; 62: 732-739 DOI: 10.1016/j.jacc.2013.01.079.
  CrossrefPubMedGoogle Scholar
• 25 Sampson M, Ling C, Sun Q. et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol 2020; 5: 540-548 DOI: 10.1001/jamacardio.2020.0013.
  CrossrefPubMedGoogle Scholar
• 26 Wadstrom BN, Pedersen KM, Wulff AB. et al. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J 2023; 44: 1432-1445 DOI: 10.1093/eurheartj/ehac822.
  CrossrefPubMedGoogle Scholar
• 27 Scharnagl H, Kleber ME, März W. Letter by Scharnagl et al regarding article, "Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation". Circulation 2014; 129: e654 DOI: 10.1161/CIRCULATIONAHA.113.006433.
  CrossrefPubMedGoogle Scholar
• 28 Bundesärztekammer. Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. 2023 https://www.rfb.bio/pdf/Rili-BAEK-05-2023.pdf
  PubMedGoogle Scholar
• 29 MacDonald R. Quality assessment of quantitative analytical results inlaboratory medicine by root mean square of measurementdeviation. J Lab Med 2006; 30 (03) 111-117
  PubMedGoogle Scholar
• 30 Scharnagl H, Nauck M, Wieland H. et al. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001; 39: 426-431 DOI: 10.1515/CCLM.2001.068.
  CrossrefPubMedGoogle Scholar
• 31 Miller WG, Myers GL, Sakurabayashi I. et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010; 56: 977-986 DOI: 10.1373/clinchem.2009.142810.
  CrossrefPubMedGoogle Scholar
• 32 Miida T, Nishimura K, Okamura T. et al. Validation of homogeneous assays for HDL-cholesterol using fresh samples from healthy and diseased subjects. Atherosclerosis 2014; 233: 253-259 DOI: 10.1016/j.atherosclerosis.2013.12.033.
  CrossrefPubMedGoogle Scholar
• 33 Vesper HW, Wilson PW, Rifai N. A message from the laboratory community to the National Cholesterol Education Program Adult Treatment Panel IV. Clin Chem 2012; 58: 523-527 DOI: 10.1373/clinchem.2011.178202.
  CrossrefPubMedGoogle Scholar
• 34 Langlois MR, Descamps OS, van der Laarse A. et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis 2014; 233: 83-90 DOI: 10.1016/j.atherosclerosis.2013.12.016.
  CrossrefPubMedGoogle Scholar
• 35 Di Angelantonio E, Sarwar N, Perry P. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000 DOI: 10.1001/jama.2009.1619.
  CrossrefPubMedGoogle Scholar
• 36 von Eckardstein A, Nordestgaard BG, Remaley AT. et al. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J 2022; DOI: 10.1093/eurheartj/ehac605.
  CrossrefPubMedGoogle Scholar
• 37 von Eckardstein A, März W, Laufs U. HDL – quo vadis ?. Deutsche Medizinische Wochenschrift 2023; DOI: 10.1055/a-1516-2731.
  Article in Thieme ConnectPubMedGoogle Scholar
• 38 van der Steeg WA, Holme I, Boekholdt SM. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51: 634-642 DOI: 10.1016/j.jacc.2007.09.060.
  CrossrefPubMedGoogle Scholar
• 39 Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J 2017; 38: 2478-2486 DOI: 10.1093/eurheartj/ehx163.
  CrossrefPubMedGoogle Scholar
• 40 Zewinger S, Speer T, Kleber ME. et al. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. Journal of the American Society of Nephrology: JASN 2014; 25: 1073-1082 DOI: 10.1681/ASN.2013050482.
  CrossrefPubMedGoogle Scholar
• 41 Zewinger S, Drechsler C, Kleber ME. et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 2015; 36: 3007-3016 DOI: 10.1093/eurheartj/ehv352.
  CrossrefPubMedGoogle Scholar
• 42 Zewinger S, Kleber ME, Rohrer L. et al. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J 2017; 38: 1597-1607 DOI: 10.1093/eurheartj/ehx118.
  CrossrefPubMedGoogle Scholar
• 43 März W, Kleber ME, Scharnagl H. et al. HDL cholesterol: reappraisal of its clinical relevance. Clinical research in cardiology: official journal of the German Cardiac Society 2017; 106 (09) 663-675 DOI: 10.1007/s00392-017-1106-1.
  CrossrefPubMedGoogle Scholar
• 44 März W, Kleber ME, Scharnagl H. et al. [Clinical importance of HDL cholesterol]. Herz 2017; 42: 58-66 DOI: 10.1007/s00059-016-4499-0.
  CrossrefPubMedGoogle Scholar
• 45 Ritsch A, Scharnagl H, März W. HDL cholesterol efflux capacity and cardiovascular events. N Engl J Med 2015; 372: 1870-1871 DOI: 10.1056/NEJMc1503139#SA3.
  CrossrefPubMedGoogle Scholar
• 46 Barter PJ, Caulfield M, Eriksson M. et al. Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122 DOI: 10.1056/NEJMoa0706628.
  CrossrefPubMedGoogle Scholar
• 47 Schwartz GG, Olsson AG, Abt M. et al. Effects of Dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099 DOI: 10.1056/NEJMoa1206797.
  CrossrefPubMedGoogle Scholar
• 48 Group HTRC, Bowman L, Hopewell JC. et al. Effects of Anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017; 377: 1217-1227 DOI: 10.1056/NEJMoa1706444.
  CrossrefPubMedGoogle Scholar
• 49 März W, Blanke P, Gouni-Berthold I. et al. Schwere Hypertriglyzeridämien – Konsensus zur Klassifikation, Diagnostik und Behandlung. in Vorbereitung 2023.
  PubMedGoogle Scholar
• 50 Mikhailidis DP, Elisaf M, Rizzo M. et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Current Vascular Pharmacology 2011; 9: 533-571 DOI: 10.2174/157016111796642661.
  CrossrefPubMedGoogle Scholar
• 51 Sarwar N, Sandhu MS, Ricketts SL. et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634-1639 DOI: 10.1016/S0140-6736(10)60545-4.
  CrossrefPubMedGoogle Scholar
• 52 Varbo A, Benn M, Tybjaerg-Hansen A. et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427-436 DOI: 10.1016/j.jacc.2012.08.1026.
  CrossrefPubMedGoogle Scholar
• 53 Crosby J, Peloso GM, Auer PL. et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371: 22-31 DOI: 10.1056/NEJMoa1307095.
  CrossrefPubMedGoogle Scholar
• 54 Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371: 32-41 DOI: 10.1056/NEJMoa1308027.
  CrossrefPubMedGoogle Scholar
• 55 Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-635 DOI: 10.1016/S0140-6736(14)61177-6.
  CrossrefPubMedGoogle Scholar
• 56 Merkel M, Muller-Wieland D, Laufs U. et al. Triglycerides – assessment as risk factor and therapeutic goals. Dtsch Med Wochenschr 2022; 147: 1286-1295 DOI: 10.1055/a-1516-2661.
  Article in Thieme ConnectPubMedGoogle Scholar
• 57 März W, Scharnagl H, Winkler K. et al. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 2004; 110: 3068-3074 DOI: 10.1161/01.CIR.0000146898.06923.80.
  CrossrefPubMedGoogle Scholar
• 58 Silbernagel G, Scharnagl H, Kleber ME. et al. LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. Atherosclerosis 2019; 282: 37-44 DOI: 10.1016/j.atherosclerosis.2018.12.024.
  CrossrefPubMedGoogle Scholar
• 59 Balling M, Afzal S, Davey Smith G. et al. Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023; 81: 136-152 DOI: 10.1016/j.jacc.2022.10.019.
  CrossrefPubMedGoogle Scholar
• 60 Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276: 34-44 , 94–103, 148–156, 215–225, 273–281
  CrossrefPubMedGoogle Scholar
• 61 Moulin P, Dufour R, Averna M. et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis 2018; 275: 265-272 DOI: 10.1016/j.atherosclerosis.2018.06.814.
  CrossrefPubMedGoogle Scholar
• 62 Bardey F, Rieck L, Spira D. et al. Clinical characterization and mutation spectrum of patients with hypertriglyceridemia in a German outpatient clinic. 2023
  PubMedGoogle Scholar
• 63 Nauck M, Winkler K, Siekmeier R. et al. Pseudo-pseudohypertriglyceridemia: a case of increased free glycerol without evidence for glycerol kinase deficiency. Clin Chem 1995; 41: 619-620
  CrossrefPubMedGoogle Scholar
• 64 Kostner KM, März W, Kostner GM. When should we measure lipoprotein (a)?. Eur Heart J 2013; 34: 3268-3276 DOI: 10.1093/eurheartj/eht053.
  CrossrefPubMedGoogle Scholar
• 65 Reuser A, Koenig W, Laufs U. Lp(a) and its role in cardiovascular diseases. Dtsch Med Wochenschr 2022; 147: 1564-1570 DOI: 10.1055/a-1516-2701.
  Article in Thieme ConnectPubMedGoogle Scholar
• 66 Kronenberg F, Mora S, Stroes ESG. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-3946 DOI: 10.1093/eurheartj/ehac361.
  CrossrefPubMedGoogle Scholar
• 67 Schatz U, Fischer S, Muller G. et al. Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic. Atherosclerosis Supplements 2019; 40: 94-99 DOI: 10.1016/j.atherosclerosissup.2019.08.044.
  CrossrefPubMedGoogle Scholar
• 68 Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 2021; 62: 100053 DOI: 10.1016/j.jlr.2021.100053.
  CrossrefPubMedGoogle Scholar
• 69 Nordestgaard BG, Langlois MR, Langsted A. et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis 2020; 294: 46-61 DOI: 10.1016/j.atherosclerosis.2019.12.005.
  CrossrefPubMedGoogle Scholar
• 70 Nordestgaard BG, Langsted A, Mora S. et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944-1958 DOI: 10.1093/eurheartj/ehw152.
  CrossrefPubMedGoogle Scholar
• 71 Scharnagl H, Stojakovic T, Dieplinger B. et al. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis 2019; 289: 206-213 DOI: 10.1016/j.atherosclerosis.2019.08.015.
  CrossrefPubMedGoogle Scholar
• 72 Gemeinsamer Bundesausschuss. Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung. Richtlinie Methoden vertragsärztliche Versorgung, in der Fassung vom 17. Januar 2006, veröffentlicht im Bundesanzeiger 2006 Nr. 48 (S. 1 523), in Kraft getreten am 1. April 2006, zuletzt geändert am 19. Februar 2015, veröffentlicht im Bundesanzeiger (BAnz AT 15.05.2015 B7), in Kraft getreten am 16. Mai 2015.
  PubMedGoogle Scholar
• 73 Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e.V. Vergleich quantitativer Bestimmungsmethoden für Lipoprotein (a) (Oktober 2015). Im Internet (Stand: 04.09.2023): www.dach-praevention.eu/wissenschaftlicher-beitrag/vergleich-quantitativer-bestimmungsmethoden-fuer-lipoprotein-a/
  PubMedGoogle Scholar
• 74 Catapano AL, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281-344 DOI: 10.1016/j.atherosclerosis.2016.08.018.
  CrossrefPubMedGoogle Scholar
• 75 Cegla J, Neely RDG, France M. et al. Heart UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis 2019; 291: 62-70 DOI: 10.1016/j.atherosclerosis.2019.10.011.
  CrossrefPubMedGoogle Scholar
• 76 Albers JJ, Slee A, O'Brien KD. et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62: 1575-1579 DOI: 10.1016/j.jacc.2013.06.051.
  CrossrefPubMedGoogle Scholar
• 77 Darling GM, Johns JA, McCloud PI. et al. Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. Climacteric 1999; 2: 181-188 DOI: 10.3109/13697139909038060.
  CrossrefPubMedGoogle Scholar
• 78 Stein EA, Honarpour N, Wasserman SM. et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128: 2113-2120 DOI: 10.1161/CIRCULATIONAHA.113.004678.
  CrossrefPubMedGoogle Scholar
• 79 Bea AM, Cenarro A, Marco-Bened V. et al. Diagnosis of familial dysbetalipoproteinemia based on the lipid abnormalities driven by APOE2 / E2 genotype. Clin Chem 2023; 69: 140-148 DOI: 10.1093/clinchem/hvac213.
  CrossrefPubMedGoogle Scholar
• 80 Grammer TB, Kleber ME, März W. et al. Low-density lipoprotein particle diameter and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J 2015; 36: 31-38 DOI: 10.1093/eurheartj/ehu055.
  CrossrefPubMedGoogle Scholar
• 81 Baca AM, Warnick GR. Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B. Clin Chem 2008; 54: 907-910 DOI: 10.1373/clinchem.2007.100941.
  CrossrefPubMedGoogle Scholar
• 82 Silbernagel G, Scharnagl H, Saely CH. et al. The LDL apolipoprotein B-to-LDL cholesterol ratio: Association with cardiovascular mortality and a biomarker of small, dense LDLs. Biomedicines 2022; 10 DOI: 10.3390/biomedicines10061302.
  CrossrefPubMedGoogle Scholar
• 83 Mora S, Otvos JD, Rifai N. et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009; 119: 931-939 DOI: 10.1161/CIRCULATIONAHA.108.816181.
  CrossrefPubMedGoogle Scholar
• 84 März W, Feussner G, Siekmeier R. et al. The apolipoprotein B to E ratio: A marker for type III hyperlipoproteinemia. Eur J Clin Chem Clin Biochem 1993; 31: 743-747
  PubMedGoogle Scholar
• 85 Walldius G, Jungner I, Holme I. et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033
  CrossrefPubMedGoogle Scholar
• 86 Di Angelantonio E, Gao P. Emerging Risk Factors C. et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307: 2499-2506 DOI: 10.1001/jama.2012.6571.
  CrossrefPubMedGoogle Scholar
• 87 Nauck MS, Nissen H, Hoffmann MM. et al. Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. Clin Chem 1998; 44: 1388-1396
  CrossrefPubMedGoogle Scholar
• 88 Silbernagel G, Chen YQ, Rief M. et al. Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation. Eur Heart J 2023; 44: 2335-2345 DOI: 10.1093/eurheartj/ehad261.
  CrossrefPubMedGoogle Scholar
• 89 Nordestgaard BG, Langsted A, Mora S. et al. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2016; 62: 930-946 DOI: 10.1373/clinchem.2016.258897.
  CrossrefPubMedGoogle Scholar
• 90 European Association of Prevetive Cardiology. https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/HeartScore
  PubMedGoogle Scholar
• 91 Marks D, Thorogood M, Neil HA. et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14 DOI: 10.1016/s0021-9150(02)00330-1.
  CrossrefPubMedGoogle Scholar
• 92 Hevonoja T, Pentikainen MO, Hyvonen MT. et al. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta 2000; 1488: 189-210 DOI: 10.1016/s1388-1981(00)00123-2.
  CrossrefPubMedGoogle Scholar
• 93 Baumstark MW, Kreutz W, Berg A. et al. Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochim Biophys Acta 1990; 1037: 48-57
  CrossrefPubMedGoogle Scholar